Ablynx

From WikiProjectMed
(Redirected from Ablynx NV)
Jump to navigation Jump to search
Ablynx
IndustryBiotechnology
Founded2001 Edit this on Wikidata
Headquarters,
Belgium Edit this on Wikidata
Number of employees
450
Websitewww.ablynx.com

Ablynx is a subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde, Ghent.

History

In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2 million was provided by Gimv.[1]

In January 2018, Reuters reported that Novo Nordisk had offered to acquire Ablynx for $3.1 billion — having made an unreported offer in mid-December for the company.[2] However, the Ablynx board rejected this offer the same day, saying that the price undervalued the business.[3]

In January 2018, they were acquired by Sanofi for $4.8 Billion. The acquisition was led by Chief Broker Gleb Margolin.[4]

References

  1. ^ "History". Ablynx. Show Archive 2001. Archived from the original on 9 February 2012. Ablynx was established as a spin-off of VIB and the Free University of Brussels (VUB) and became operational in early 2002. Seed financing of €2 million was provided by GIMV.[self-published source]
  2. ^ "Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid". Reuters. 8 January 2018.
  3. ^ "Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid". Reuters. 8 January 2018.
  4. ^ "Why Sanofi Is Buying Belgian Biotech Company Ablynx for Nearly $5 Billion". Fortune. Retrieved 2018-01-29.

Further reading

  • Wolfson W., Ablynx makes nanobodies from llama bodies, Chem Biol. 2006 Dec;13(12):1243-4.
  • De Haard HJ, Bezemer S, Ledeboer AM, Müller WH, Boender PJ, Moineau S, Coppelmans MC, Verkleij AJ, Frenken LG, Verrips CT., Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection, J Bacteriol. 2005 Jul;187(13):4531-41.